Premium
EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDY
Author(s) -
Visentin A.,
Mauro F. R.,
Cibien F.,
Vitale C.,
Reda G.,
Fresa A.,
Ciolli S.,
Pietrasanta D.,
Marchetti M.,
Murru R.,
Gentile M.,
Rigolin G. M.,
Quaglia F. M.,
Scarfò L.,
Sportoletti P.,
Pravato S.,
Romano Gargarella L.,
Facco M.,
Piazza F.,
Marchetti M.,
Coscia M.,
Laurenti L.,
Molica S.,
Pizzolo G.,
Foà R.,
Cuneo A.,
Trentim L.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.46_2880
Subject(s) - ibrutinib , medicine , discontinuation , chronic lymphocytic leukemia , ighv@ , clinical endpoint , oncology , leukemia , clinical trial